Verona Pharma PLC VRNA
We take great care to ensure that the data presented and summarized in this overview for Verona Pharma plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VRNA
View all-
Janus Henderson Group PLC London, X06.13MShares$645 Million0.3% of portfolio
-
Perceptive Advisors LLC New York, NY5.51MShares$579 Million22.87% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y94.13MShares$434 Million16.48% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$356 Million16.88% of portfolio
-
Rtw Investments, LP New York, NY3.05MShares$321 Million4.43% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.72MShares$286 Million4.88% of portfolio
-
Goldman Sachs Group Inc New York, NY2.62MShares$275 Million0.04% of portfolio
-
Abingworth LLP London, X02.46MShares$259 Million21.3% of portfolio
-
Nea Management Company, LLC Timonium, MD2.26MShares$238 Million17.75% of portfolio
-
Summit Partners Public Asset Management, LLC Boston, MA2.14MShares$226 Million6.35% of portfolio
Latest Institutional Activity in VRNA
Top Purchases
Top Sells
About VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Insider Transactions at VRNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 01
2025
|
Andrew Fisher General Counsel |
SELL
Open market or private sale
|
Direct |
9,584
-2.24%
|
$124,592
$13.14 P/Share
|
|
Aug 01
2025
|
Andrew Fisher General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,888
+4.66%
|
-
|
|
Aug 01
2025
|
Lisa Deschamps Director |
SELL
Open market or private sale
|
Direct |
9,464
-10.03%
|
$123,032
$13.14 P/Share
|
|
Aug 01
2025
|
Lisa Deschamps Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+20.28%
|
-
|
|
Aug 01
2025
|
Kenneth Cunningham Director |
SELL
Open market or private sale
|
Direct |
10,808
-11.93%
|
$140,504
$13.14 P/Share
|
|
Aug 01
2025
|
Kenneth Cunningham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+20.95%
|
-
|
|
Aug 01
2025
|
Michael Austwick Director |
SELL
Open market or private sale
|
Direct |
11,288
-47.03%
|
$146,744
$13.14 P/Share
|
|
Aug 01
2025
|
Michael Austwick Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+50.0%
|
-
|
|
Aug 01
2025
|
Christina Ackermann Director |
SELL
Open market or private sale
|
Direct |
1,808
-2.74%
|
$23,504
$13.14 P/Share
|
|
Aug 01
2025
|
Christina Ackermann Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+26.7%
|
-
|
|
Aug 01
2025
|
Kathleen A. Rickard Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
58,336
-2.19%
|
$758,368
$13.14 P/Share
|
|
Aug 01
2025
|
Kathleen A. Rickard Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
70,888
+2.59%
|
-
|
|
Aug 01
2025
|
Mark W Hahn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
208,912
-1.65%
|
$2,715,856
$13.14 P/Share
|
|
Aug 01
2025
|
Mark W Hahn Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
255,696
+1.98%
|
-
|
|
Aug 01
2025
|
Martin Edwards Director |
SELL
Open market or private sale
|
Direct |
10,808
-6.4%
|
$140,504
$13.14 P/Share
|
|
Aug 01
2025
|
Martin Edwards Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+12.45%
|
-
|
|
Aug 01
2025
|
David R Ebsworth Director |
SELL
Open market or private sale
|
Direct |
1,904
-0.22%
|
$24,752
$13.14 P/Share
|
|
Aug 01
2025
|
David R Ebsworth Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+2.65%
|
-
|
|
Aug 01
2025
|
David Zaccardelli President and CEO |
SELL
Open market or private sale
|
Direct |
208,912
-1.54%
|
$2,715,856
$13.14 P/Share
|
|
Aug 01
2025
|
David Zaccardelli President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
255,696
+1.85%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 3.54M shares |
|---|---|
| Open market or private purchase | 101K shares |
| Grant, award, or other acquisition | 3.1M shares |
| Bona fide gift | 1 shares |
| Open market or private sale | 9.22M shares |
|---|---|
| Payment of exercise price or tax liability | 1.18M shares |
| Bona fide gift | 64K shares |